SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
ULBI 6.860-1.0%10:54 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (1986)12/7/2010 1:52:57 AM
From: richardred   of 7239
 
UPDATE 1-Spectrum Pharma says cancer drug shows promise; shrs up


Mon Dec 6, 2010 5:51pm EST

* Mid-stage trial sees 84 pct response rate

* Late-stage study shows 35 months progression-free survival

* Shares up 10 pct

Dec 6 (Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said a mid-stage trial of its injection for non-Hodgkin's lymphoma (NHL), a type of cancer, as a first-line therapy showed positive results, sending its shares up 10 percent.

Patients who were given a single dose of the drug Zevalin without upfront chemotherapy showed a response rate of 84 percent, the company said.

Spectrum also said a late-stage trial of the drug showed nearly three years of progression-free survival benefit in patients with NHL after partial or complete response to first-line chemotherapy.

The company said it plans to submit the data for consideration to the U.S. Food and Drug Administration to remove the bioscan requirement before taking the injection.

Spectrum shares, which have risen 18 percent since the U.S. FDA accepted its cancer drug for review in November, were up 10 percent at $5.96 in extended trade on Monday. (Reporting by Shravya Jain in Bangalore; Editing by Vinu Pilakkott)

reuters.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News